Cell & Gene | 01 April 2024 | Analysis
Addressing Accessibility and Affordability of Cell & Gene Therapies
The most sought-after and hot sector in the pharmaceutical industry, which has witnessed an outpouring of bill...Read more
Singapore | 01 April 2024 | Opinion
Addressing Challenges in Cell Therapy Manufacturing
Cancer research has come a long way. Along with technology advancements, the basic options for treating cancer...Read more
Cell & Gene | 01 April 2024 | Opinion
Engineering CAR T-cell sharpshooters
Ideally, the antigen for a traditional CAR T-cell (or a T-cell) would be universally and homogeneously express...Read more
White paper / Reports | 01 April 2024 | Analysis
Biotech and Pharma's March Shake-Up: Layoffs Signal Industry Evolution
March 2024 has been marked by a series of layoffs in the biotech and pharmaceutical sector, raising concerns a...Read more
Singapore | 05 April 2024 | News
Singapore approves new asthma indication for GSK's Trelegy Ellipta
GSK Singapore has announced that the Health Sciences Authority (HSA) has approved a new indication and a new s...Read more
Japan | 29 March 2024 | News
Eisai to divest rights for Merislon and Myonal in Japan to Kaken Pharma for ¥ 3.8 B
Eisai Co. has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment...Read more
China | 19 February 2024 | News
Biocytogen Pharma Beijing and Gilead enter into multi-target antibody collaboration agreement
Biocytogen Pharmaceuticals (Beijing) Co. has announced an antibody evaluation and option agreement with A...Read more
Singapore | 17 April 2024 | News
SCG Cell Therapy and A*STAR launch joint labs for cellular immunotherapies in Singapore
SCG Cell Therapy (SCG) and the Agency for Science, Technology and Research (A*STAR) have announced the launch ...Read more
India | 21 March 2024 | News
Biological E to manufacture oral cholera vaccine for India and global markets
South Korea-based International Vaccine Institute (IVI) has commenced a technology transfer of simplified Oral...Read more
New Zealand | 08 March 2024 | News
Kimer Med inks contract worth NZD $1.3 M to pioneer antiviral drug advances
Kimer Med, a New Zealand (NZ)-based biotech startup, has signed a contract valued at up to $750,000 (NZD$1.3 m...Read more
Korea | 09 April 2024 | News
Korea-based Medit unveils next evolution of Intraoral Scanners
South Korea-based Medit, a leading provider of dental 3D scanners and digital dentistry solutions, has an...Read more
Australia | 02 April 2024 | News
Australia suggests use of ultrasound therapy as promising treatment for Alzheimer’s disease
Australia's University of Queensland (UQ) researchers have found targeting amyloid plaque in the brain is not ...Read more
Europe | 18 March 2024 | News
Korean startup Lunit delivers AI-powered cancer screening solution to France and Portugal
Lunit, a leading provider of artificial intelligence (AI)-powered solutions for cancer diagnostics and therape...Read more
Korea | 21 March 2024 | News
Merck invests € 300+ M in new life science production site in Korea
Merck invests more than €300 million into a new Bioprocessing Production Centre in Daejeon, South Korea. ...Read more
Singapore | 19 March 2024 | News
WuXi Biologics to establish new CRDMO facility in Singapore
China's WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organisation (CRDMO)...Read more
Korea | 09 February 2024 | News
Samsung Biologics & LegoChem Biosciences in Korea team up for ADC development
South Korea-based Samsung Biologics, a global contract development and manufacturing organisation (CDMO), has ...Read more
Addressing Accessibility and Affordability of CELL & GENE THERAPIES
Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry. Quite a few companies in the field are making remarkable advancements toward potentially curative treatments for challenging diseases using groundbreaking science. With lower R&D development costs than in advanced markets, China is becoming an attractive market for the development of CGT, and therefore may emerge as a strong competitor of overseas-made CGT, notes a GlobalData report. Bayer AG, recently announced the global expansion of its life science incubator network, Bayer Co. Lab, to Shanghai, China and Kobe, Japan. The new site in China will focus on oncology and CGT innovations. While India lags behind China in the production of cell and gene therapies, a wave of new biotech startups is emerging to address this challenge. Immuneel Therapeutics and ImmunoACT are currently developing CAR-T cell therapies. The latter’s NexCAR19 therapy received approval from India's Central Drug Standards Control Organisation (CDSCO) for treating relapsed or refractory B-cell lymphomas and leukaemia. Despite a steady stream of regulatory approvals and promising growth prospects, the high manufacturing costs associated with these therapies often render them inaccessible to the majority of patients. To address this issue, companies are actively striving to streamline and optimise the highly intricate and labour-intensive process of cell and gene therapy manufacturing.